Vascular endothelial growth factor expression in osteosarcoma
- PMID: 16826116
- DOI: 10.1097/01.blo.0000205877.05093.c9
Vascular endothelial growth factor expression in osteosarcoma
Abstract
Vascular endothelial growth factor expression by osteosarcomas at biopsy has been shown to have a negative influence on survival. Whether it continues to be expressed and influence outcome in tumors after neoadjuvant chemotherapy has not been determined. To determine if a high-degree of vascular endothelial growth factor expression by the surviving osteosarcoma cells in the resected tumor has a negative influence on prognosis, we retrospectively reviewed 52 patients with Stage IIB osteosarcoma around the knee, 48 of whom received neoadjuvant chemotherapy. Vascular endothelial growth factor expression by the surviving tumor cells in the surgically resected specimens was determined by immunohistochemical staining. Followup was for a minimum of 92 months. The presence of vascular endothelial growth factor expression in greater than 25% of tumor cells was independently associated with a reduced overall and disease-free survival rate.
Level of evidence: Prognostic study, Level II (retrospective study). See the Guidelines for Authors for a complete description of levels of evidence.
Similar articles
-
Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis.Clin Cancer Res. 2000 Feb;6(2):572-7. Clin Cancer Res. 2000. PMID: 10690541
-
Ezrin expression predicts survival in stage IIB osteosarcomas.Clin Orthop Relat Res. 2007 Jun;459:229-36. doi: 10.1097/BLO.0b013e3180413dbf. Clin Orthop Relat Res. 2007. PMID: 17353802
-
Expression of osteopontin and vascular endothelial growth factor in benign and malignant bone tumors.Virchows Arch. 2002 Oct;441(4):345-9. doi: 10.1007/s00428-002-0671-4. Epub 2002 Jul 3. Virchows Arch. 2002. PMID: 12404059
-
A preliminary investigation of Beta-hCG expression in patients with osteosarcoma.J Bone Joint Surg Br. 2012 Mar;94(3):419-24. doi: 10.1302/0301-620X.94B3.27679. J Bone Joint Surg Br. 2012. PMID: 22371553 Review.
-
Moving towards non-invasive assessments of prognosis in osteosarcoma.Pediatr Blood Cancer. 2010 Apr;54(4):497-8. doi: 10.1002/pbc.22387. Pediatr Blood Cancer. 2010. PMID: 20091706 Review. No abstract available.
Cited by
-
Up-regulated isocitrate dehydrogenase 1 suppresses proliferation, migration and invasion in osteosarcoma: in vitro and in vivo.Cancer Lett. 2014 Apr 28;346(1):114-21. doi: 10.1016/j.canlet.2013.12.020. Epub 2013 Dec 22. Cancer Lett. 2014. PMID: 24368190 Free PMC article.
-
Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines.Oncogenesis. 2012 Nov 19;1(11):e34. doi: 10.1038/oncsis.2012.34. Oncogenesis. 2012. PMID: 23552467 Free PMC article.
-
MicroRNAs signatures, bioinformatics analysis of miRNAs, miRNA mimics and antagonists, and miRNA therapeutics in osteosarcoma.Cancer Cell Int. 2020 Jun 17;20:254. doi: 10.1186/s12935-020-01342-4. eCollection 2020. Cancer Cell Int. 2020. PMID: 32565738 Free PMC article. Review.
-
Impact of vascular endothelial growth factor expression on overall survival in patients with osteosarcoma: a meta-analysis.Tumour Biol. 2014 Mar;35(3):1745-9. doi: 10.1007/s13277-014-1692-8. Epub 2014 Feb 11. Tumour Biol. 2014. PMID: 24515658
-
The Osteosarcoma Microenvironment: A Complex But Targetable Ecosystem.Cells. 2020 Apr 15;9(4):976. doi: 10.3390/cells9040976. Cells. 2020. PMID: 32326444 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
